Making Medicines
Accessible and
Affordable.

A nonprofit building a new model to develop and manufacture life-saving medicines that patients and our healthcare system can afford.

About Our Model arrow_forward

The Impact of High Cost Medicines

High drug prices put life-saving medicines out of reach for patients and place an unsustainable burden on our healthcare system.

Accessibility Crisis

57%

Americans struggle to afford essential daily medications.

National Health Council Benchmark

Price Disparity

4.4×

U.S. brand drug prices exceed other developed nations for identical essential medications.

RAND Corporation Comparison

Treatment Adherence

30%

Patients skip doses or cut pills to make costly prescriptions last, risking severe health outcomes.

KFF Clinical Adherence Study

Nonprofit Capital for
Affordable Medicines

Tabitha Quest was founded to make life-saving medicines accessible and affordable for patients and our healthcare system. We believe accessibility should be a core objective of drug development and integrated across development, manufacturing, and pricing.

Our nonprofit-controlled structure combines philanthropic and other mission-driven capital with private investment to support drug development. Affordability shapes decisions from how medicines are financed and developed to how they are manufactured and ultimately priced. This structure allows an increasing share of the economics to be directed toward lower prices, broader patient access, domestic manufacturing, and the development of additional medicines.

Modern biomanufacturing facility cleanroom

Our Core Pillars

health_and_safety

Affordability & Access

Making life-saving medicines more affordable and accessible by building lower prices into how they are developed, manufactured, and brought to patients.

precision_manufacturing

Domestic Biomanufacturing

Building domestic biologics capacity that makes critical medicines on American soil to ensure supply chain integrity and rapid local scalability.

shield_with_heart

National Preparedness

Ensuring America's pharmaceutical infrastructure is ready to combat future biological threats and drug shortages with rapid, resilient surge capabilities.